TRML 28.45 Tourmaline Bio, Inc.
| Range: | 9.18-48.31 | Vol Avg: | 189840 | Last Div: | 15.12 | Changes: | -2.33 |
| Beta: | 0 | Cap: | 0.64B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri May 07 2021 | Empoloyees: | 70 | ||
| CUSIP: | CIK: | 0001827506 | ISIN: | US89157D1054 | Country: | US | |
| CEO: | Dr. Sandeep C. Kulkarni M.D. | Website: | https://www.tourmalinebio.com | ||||
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow